Astemizole Veterinary Grade API is incorporated at 2.5% w/w into a direct-compression tablet for canine atopic dermatitis because the compounding reference dose of 0.5 mg/kg bodyweight per 24 h corresponds to a 5 mg active unit for a 10 kg reference dog when total tablet weight is fixed at 200 mg. The API is not added directly to the final blend; a staged pre-blend is prepared at 10% w/w in spray-dried lactose monohydrate using a 10 L bin blender at 25 rpm for 10 min, then diluted through a 600 L drum blender with microcrystalline cellulose PH102, low-moisture maize starch, pregelatinised starch 1500, and 0.25% w/w colloidal silicon dioxide until active content reaches 2.5% w/w. Process failures observed on production batches are dominated by content uniformity drift when API particle size exceeds 75 µm D90; incoming lots are therefore pre-sieved through a 250 µm screen and passed through a conical mill with a 0.6 mm screen before pre-blending. Compression operates on a rotary tablet press with 16-station Euro-B tooling, 8 kN precompression, 60–80 kN main compression, punch speed 60–80 rpm, and tablet hardness controlled at 60–80 N; friability remains below 1.0% under USP <1216>. Dissolution testing is performed according to USP <711> Apparatus 2, 50 rpm paddle, 900 mL of 0.1 M hydrochloric acid at 37.0°C, with Q not less than 80% at 30 min. The terminal product is a round, biconvex, uncoated tablet for long-term antipruritic therapy in dogs with confirmed atopic dermatitis; the tablet is packaged in 10-unit aluminium-aluminium blister strips to limit light and moisture uptake. Compliance relies on USP <905> uniformity of dosage units, USP <1216> friability, USP <711> dissolution, VICH GL11 for impurities in new veterinary drug substances, and ICH Q3D for elemental impurities. Because astemizole inhibits the hERG channel and exhibits CYP3A4-mediated drug interactions, concurrent use with ketoconazole, itraconazole, erythromycin, or clarithromycin is contraindicated; the production batch records also specify that stored tablets not exceed 25°C and 60% relative humidity, because free-base agglomerates may re-form at higher humidity and reduce dissolution.

What Limits Fill Weight Variability in Feline Capsule Production?

For feline allergic dermatitis and eosinophilic granuloma complex, the same 0.5 mg/kg once-daily dose is translated into a size 4 hard gelatin or HPMC capsule containing 2.5 mg astemizole in a 100 mg net fill, giving a 2.5% w/w active ratio. Fill weight variability is the primary process conflict because at 100 mg total fill the API constitutes only 2.5 mg per unit; a ±3 mg fill deviation already represents a ±12% dose deviation, exceeding the acceptance criteria of USP <905> content uniformity. To control this, the blend is prepared in a 300 L V-blender at 25 rpm for 15 min with microcrystalline cellulose PH101, pregelatinised starch 1500, and 0.5% w/w magnesium stearate, and the active is introduced as a 5% w/w pre-blend in mannitol before geometric dilution. Dosator-type capsule machines are set to a target fill weight of 100 mg with 20-capsule in-process weight checks every 15 min; any machine stop longer than 2 min requires the first 10 capsules to be discarded after restart to account for powder densification in the dosator chamber. The terminal product is a two-piece hard capsule for oral administration in cats, often hidden in a small amount of food or administered via a pilling device. Compliance is anchored to USP <905>, USP <711> with dissolution in 0.1 M HCl, VICH GL11, ICH Q3D, and ICH Q3C residual solvent limits for capsule shell manufacturing. The main limitation is that published feline-specific pharmacokinetic data for astemizole is limited; the 0.5 mg/kg dose is an extralabel clinical practice and requires veterinary oversight, especially in cats with concurrent hepatic disease.

Solubilisation of Astemizole Veterinary Grade API for a 1.0 mg/mL aqueous oral solution is governed by the free base form’s poor water solubility and requires a buffered co-solvent vehicle rather than simple dissolution in purified water. The starting formulation is 0.1% w/v astemizole, 15% w/v polyethylene glycol 300, 15% w/v propylene glycol, 0.2% w/v citric acid, 0.05% w/v potassium sorbate, and purified water to volume, adjusted with sodium citrate to pH 4.5 ±0.2. Manufacturing is performed in a 316L stainless steel jacketed vessel at 25°C with a low-shear impeller at 150 rpm for 30 min, followed by passage through a 0.45 µm polyethersulfone clarifying filter prior to filling into 30 mL amber PET bottles with polyethylene child-resistant caps. The terminal product is a multidose oral solution intended for dogs and cats that resist tablets or require bodyweight-scaled doses below the available tablet strength; dosing is delivered via a graduated 1 mL oral syringe. In-process specifications include pH 4.5 ±0.2, density 1.02–1.06 g/mL, assay 95–105% of label, and a visual precipitation check after 48 h at 2–8°C. The solution is manufactured under nonsterile compounding conditions when prepared in a veterinary pharmacy, and therefore follows USP <795>; finished product microbial quality is assessed under USP <61> enumeration and USP <51> antimicrobial effectiveness testing. The critical boundary is that astemizole precipitates from this vehicle if pH rises above 5.5 or if the solution is diluted with unbuffered water; the product must not be mixed in aluminium feeding bowls or with strongly acidic juices that alter ionic strength. Published stability data for this exact co-solvent system are limited, so a 6-month accelerated stability study at 40°C and 75% relative humidity should be completed before assigning a beyond-use date longer than 30 days.

When a Parenteral Route Is Requested, Solubility and hERG Safety Data Drive Process Design

The injectable presentation is not a standard approved veterinary line and published efficacy data in target species are limited; this scenario is restricted to investigational hospital use or extemporaneous parenteral compounding under emergency veterinary supervision. Astemizole is formulated as a lyophilised powder containing 5 mg per vial by aseptic filling of a bulk solution at 0.5 mg/mL active, equivalent to 0.05% w/v, with 20% w/v hydroxypropyl-β-cyclodextrin and 10 mM citrate buffer adjusted to pH 4.0; the fill volume is 10 mL per 20 mL type I glass vial, yielding 5 mg astemizole after lyophilisation. The bulk solution is sterile-filtered through a 0.22 µm polyvinylidene fluoride membrane into depyrogenated vials, then lyophilised with a primary drying step at −35°C for 20 h and a secondary drying step at 25°C for 8 h under 0.2 mbar chamber pressure. The terminal product is a sterile lyophilised cake for reconstitution with 10 mL water for injection, intended for slow intravenous administration in acute hypersensitivity reactions where the patient cannot tolerate oral treatment. The major process risk is not bacterial contamination but the cardiac safety of the active: astemizole blocks hERG-mediated outward potassium currents, and the formulation itself changes the free drug concentration profile after rapid injection. For this reason, ICH S7B hERG screening and a preformulation solubility-toxicity curve are mandatory before batch manufacture, and USP <71> sterility, USP <85> bacterial endotoxins, and EU GMP Annex 1 aseptic processing requirements apply. The operational boundary is strict: the product must not be injected rapidly as a bolus, must not be co-administered with CYP3A4 inhibitors, and must only be used with continuous ECG monitoring because published safe parenteral dose ranges for dogs, cats, and horses are limited.

Sachet-packed granules are produced for dogs that will eat a wet food meal but reject tablets or capsules. The active is dry-blended into a wet-granulation formulation at 0.1% w/w to give a 5 g unit dose containing 5 mg astemizole, matching the 0.5 mg/kg dose for a 10 kg dog. Granulation is carried out in a high-shear mixer with a 300 L bowl at 150 rpm impeller speed and 1500 rpm chopper speed for 3 min, using a binder solution of 5% w/w pregelatinised starch in purified water heated to 60°C; mannitol is used as the main filler instead of lactose to reduce hygroscopicity and avoid browning reactions during fluid-bed drying. The wet mass is screened through a 1.0 mm sieve and dried in a Glatt GPCG fluid-bed dryer with 45°C inlet air and a 0.5 m/s superficial air velocity until loss on drying is below 2.0% w/w; the dried granules are then passed through a 355 µm and 710 µm sieve stack to remove both dust and oversize agglomerates. The terminal product is a unit-dose granule sachet that is mixed into a single canned meal immediately before feeding to prevent drug loss in uneaten food. Compliance includes USP <921> Karl Fischer water determination, USP <795> for nonsterile compounding when prepared in pharmacy batch sizes, VICH GL11 for impurity control, and ICH Q3D elemental impurity risk assessment. The explicit process boundary is that the sachet is not a free-choice feed additive; splitting the 5 g unit over multiple meals produces unpredictable dosing, and the granule must not be mixed with hot food exceeding 40°C because drug degradation and granule softening may alter content uniformity.

Premix Stock Powder for Compounding Pharmacies and Veterinary Hospital Dispensaries

Astemizole Veterinary Grade API is supplied as a 2.0% w/w stock premix in anhydrous lactose with 1.0% w/w colloidal silicon dioxide, filled into 100 g high-density polyethylene containers after 20 min of tumble blending. The premix is not intended for direct administration; it is a pharmacy intermediate that is geometrically diluted by the compounding pharmacist to produce individually weighed capsules, small-volume oral suspensions, or medicated oral pastes. Addition ratio in the stock is 20 mg astemizole per 1 g premix; for a 5 mg dose, the pharmacist weighs 250 mg stock and further dilutes with lactose or a suspension vehicle. Compliance is governed by USP <795> for nonsterile compounding, ICH Q3C residual solvents, and VICH GL11 for API-related impurities. The main operational boundary is moisture ingress: the stock must be stored below 25°C in the original container and used within 90 days after first opening because the non-hermetic closure used in pharmacy dispensing allows humidity to increase above 60% relative humidity and can cause agglomeration. This terminal product class is therefore not a finished patient-ready medicine but a controlled stock formulation for licensed pharmacy processing.